Genfit (FRA:XUPB) Valuation Rank


FRA:XUPB Genfit SA FRA:XUPB
65 GF Score
Price €6.15
GF Value €4.16
! 10 Warning Signs
View Full Analysis

What is Genfit Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Genfit Valuation Rank Related Terms

FRA:XUPB
65GF Score
Genfit SA FRA:XUPB
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genfit (FRA:XUPB) Overvalued in 2026?

Based on GuruFocus' analysis, Genfit stock appears to be overvalued. The current stock price of €6.15 is trading 47.8% above its estimated GF Value™ of €4.16.

Key valuation signals for FRA:XUPB:

  • Valuation Rank:
  • GF Value™: €4.16 vs. price of €6.15 (47.8% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the FRA:XUPB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genfit Business Description

Address 885, Avenue Eugene Avinee, Parc Eurasante, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
65GF Score

Get the complete analysis for FRA:XUPB

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.15
Price
€4.16
GF Value